To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2016

Conditions
RA
Interventions
DRUG

Sarilumab

Pharmaceutical form: Solution Route of administration: Subcutaneous

DEVICE

Auto-Injector Device (AID)

DEVICE

Pre-filled Syringe (PFS)

DRUG

Methotrexate

Dispensed according to local practice.

DRUG

Sulfasalazine

Dispensed according to local practice.

DRUG

Leflunomide

Dispensed according to local practice.

DRUG

Hydroxychloroquine

Dispensed according to local practice.

Trial Locations (53)

2013

Investigational Site Number 710001, Johannesburg

4001

Investigational Site Number 710003, Durban

6045

Investigational Site Number 710051, Port Elizabeth

7405

Investigational Site Number 710011, Cape Town

7500

Investigational Site Number 710007, Cape Town

7530

Investigational Site Number 710050, Bellville

12208

Investigational Site Number 840039, Albany

16635

Investigational Site Number 840009, Duncansville

19611

Investigational Site Number 840062, Reading

21740

Investigational Site Number 840202, Hagerstown

29406

Investigational Site Number 840016, North Charleston

32804

Investigational Site Number 840236, Orlando

33143

Investigational Site Number 840220, South Miami

33185

Investigational Site Number 840229, Miami

34684

Investigational Site Number 840155, Palm Harbor

35801

Investigational Site Number 840152, Huntsville

38305

Investigational Site Number 840025, Jackson

38801

Investigational Site Number 840037, Tupelo

44690

Investigational Site Number 484002, Guadalajara

45219

Investigational Site Number 840224, Cincinnati

48504

Investigational Site Number 840232, Flint

49048

Investigational Site Number 840233, Kalamazoo

64460

Investigational Site Number 484005, Monterrey

68516

Investigational Site Number 840112, Lincoln

73103

Investigational Site Number 840002, Oklahoma City

74135

Investigational Site Number 840065, Tulsa

75007

Investigational Site Number 840230, Carrollton

75042

Investigational Site Number 840237, Plano

75150

Investigational Site Number 840074, Mesquite

75231

Investigational Site Number 840001, Dallas

77034

Investigational Site Number 840020, Houston

Investigational Site Number 840239, Houston

Investigational Site Number 840241, Houston

Investigational Site Number 840242, Houston

78705

Investigational Site Number 840038, Austin

79424

Investigational Site Number 840069, Lubbock

80304

Investigational Site Number 840223, Boulder

85381

Investigational Site Number 840221, Peoria

95661

Investigational Site Number 840226, Roseville

97000

Investigational Site Number 484004, Mérida

115404

Investigational Site Number 643020, Moscow

115522

Investigational Site Number 643001, Moscow

192242

Investigational Site Number 643008, Saint Petersburg

650000

Investigational Site Number 643006, Kemerovo

2520997

Investigational Site Number 152007, Viña del Mar

5311092

Investigational Site Number 152005, Osorno

Unknown

Investigational Site Number 152050, Santiago

Investigational Site Number 152014, Talca

15-351

Investigational Site Number 616002, Bialystok

20-582

Investigational Site Number 616005, Lublin

02-118

Investigational Site Number 616004, Warsaw

02-653

Investigational Site Number 616017, Warsaw

50-044

Investigational Site Number 616012, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY